Posted by Michael Wonder on 08 May 2025
MHRA approves teprotumumab as the first UK treatment for adults with moderate to severe thyroid eye disease
7 May 2025 - The MHRA has today approved teprotumumab (Tepezza).
This is the first medicine to be licensed in the UK for adult patients with moderate to severe thyroid eye disease.
